Driving reinvestment in R&D for antibiotics and advocating their responsible use

Slide sets

Bioinfect 2017 Sq Ad (1000x1000)-2

Antibacterial Drug R&D  – Medical Need and Public Support

Delivered by U. Theuretzbacher – Center for Anti-Infective Agents, Vienna, Austria
2017 BioInfect Conference held on 02 November 2017, Alderley Park Conference Centre, Cheshire

 

 

 

 

ursule-imed-pres-thumbnailEcology and environmental drivers of antibiotic resistance

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
International Meeting on Emerging Diseases and Surveillance, held on 4-7 November 2016, Vienna.

 

 

theuretzbacher_world-health-summit-2016

Strengthening AMR R&D by coordination, cooperation and knowledge exchange

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
World Health Summit side event, “Global expert network conference on innovations in antimicrobial drug research and development”, Berlin, October 2016

 

 

 

Outterson_PaccarbPresentation_June 2016Economic incentives for antibiotics: The DRIVE-AB approach

Delivered by Kevin Outterson, Boston University School of Law and Chatham House
Presidential Advisory Council on Combating Antibiotic Resistant Bacteria meeting (PACCARB) meeting,  June 2016

 

 

How to stimulate and incentivize the development of needed, new antibioticsHow to stimulate and incentivize the development of needed, new antibiotics

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Bio2Device Group, Palo Alto, USA, June 2016

 

 

Colson_SMDM_June 2016Review of the health technology assessment (HTA) process for antibiotics in Europe

Delivered by Abigail Colson, University of Strathclyde
16th Biennial European Conference, London, June 2016

 

 

Groningen_Theuretzbacher presentation coverNew economic models for antibiotic R&D

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Gulf Congress of Clinical Microbiology and Infectious Disease, Dubai, May 2016

 

 

Theuretzbacher_GCCMID presentation_May 2016Worldwide initiatives to control AMR and role of antimicrobial stewardship

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Antibiotics-Now!, University of Groningen, May 2016

 

 

Theuretzbacher_ICID 2016_presentation slide

The antibiotic pipeline: What can we expect?

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
17th International Congress on Infectious Diseases (ICID), Hyderabad, India, 2016

 

 

Ardal_ICID 2016_slide cover

Incentivizing Antibiotic Innovation

Delivered by Christine Årdal, Norwegian Institute of Public Health
17th International Congress on Infectious Diseases (ICID), Hyderabad, India, 2016

 

 

John Arne slide set WHO DNDi november 2015 meetingReview of possible funding/incentive mechanisms and opportunities

Delivered by John-Arne Røttingen, Norwegian Institute of Public Health
WHO & DNDi Technical Consultation: Investing in the development of new antibiotics and their conservationGeneva, 2015

 


John-Arne HTA stakeholder mtng pres

DRIVE-AB: Driving Re-Investment in R&D and Responsible Antibiotic Use 

Delivered by John-Arne Røttingen, Norwegian Institute of Public Health
First HTA stakeholder meeting, Oslo, 2015

 

Ramanan Latsis Symposium 2015 pres image

Economics of Antibiotic Resistance

Delivered by Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy (CDDEP)
Latsis Symposium, Zürich, 2015

 


Christine DRIVE-AB Washington meeting presCreating, Testing and Validating New Economic Models for Antibiotic R&D

Delivered by Christine Årdal, Norwegian Institute of Public Health
Stimulating the antimicrobial pipeline: A global perspective, Washington DC, 2015

 

 

Stephan Harbarth Geneva Pharma Forum presWhy should we care about multi-resistant bacteria? Clinical impact and public health implications

Delivered by Prof Stephan Harbarth, Université de Genève / Infection Control Program
Geneva Pharma Forum, Geneva, 2015

 

 

John Rex IFPMA presEnabling drug discovery and development to address the crisis of antibacterial resistance: New tools, new pathways and remaining challenges

Delivered by Dr John Rex, AstraZeneca
Geneva Pharma Forum, Geneva, 2015

 

 

Ursula SME mtng 2015 Intro slideDRIVE-AB and the role of SMEs in antibacterial drug R&D

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
DRIVE-AB Stakeholder Meeting, 2015, London, 2015

 

 

PHE presDevelopment of National Antimicrobial Stewardship and Prescribing Competences

Delivered by Diane Ashiru-Oredope, Public Health England
BSAC Spring Meeting, London, 2014

 

 

Back to Resources